- Home
- QURE vs SLS Comparison
QURE vs SLS Comparison
Compare QURE & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | SLS |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | Netherlands | United States |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.7B |
| IPO Year | 2013 | 2007 |
Fundamental Metrics
Financial Performance| Metric | QURE | SLS |
|---|---|---|
| Price | $43.04 | $11.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 1 |
| Target Price | ★ $45.00 | $10.00 |
| AVG Volume (30 Days) | 1.1M | ★ 7.4M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.67 | ★ 50.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $126.12 | N/A |
| Revenue Next Year | $200.43 | $110.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.73 | $1.39 |
| 52 Week High | $71.50 | $15.88 |
Technical Indicators
Market Signals| Indicator | QURE | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 46.24 | 41.56 |
| Support Level | $39.50 | $11.43 |
| Resistance Level | $51.09 | $15.77 |
| Average True Range (ATR) | 2.05 | 1.11 |
| MACD | -0.66 | -0.31 |
| Stochastic Oscillator | 21.68 | 18.33 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.